Company / Cash & Equivalents
LENZ Therapeutics, Inc. Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$25.2M
FY2025
5-year range
$20.2M / $377.0M
FY2021-FY2025
Trend
+24.9%
vs FY2024
Sector context
#199 of 207
Health Care
What the data says
Among 207 Health Care companies, LENZ Therapeutics, Inc. is in the bottom 4% for cash & equivalents. Cash & Equivalents returned to growth in FY2025 after 3 years of decline, reaching $25M.
Based on SEC 10-K filings.
$25M in FY2025 with a 5-year CAGR of +4.9%.
Declined from $35M to $25M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -19.2%
- 5-Year CAGR
- +4.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 207This company $25.2M Sector average $669.5M
▼
-96.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +4.9%, indicating consistent growth.
- In FY2025, cash & equivalents increased 24.9% year-over-year.
- Ranks #199 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.71 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $25.2M | +24.9% |
| FY2024 | $20.2M | -42.6% |
| FY2023 | $35.1M | -26.4% |
| FY2022 | $47.7M | -87.3% |
| FY2021 | $377.0M | +1805.7% |
| FY2020 | $19.8M | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026